Abstract
This issue of Translational Lung Cancer Research ( TLCR ) focuses on advances in lung cancer immunotherapy. Lung cancer has traditionally been considered to be an immune resistant disease. However, great advances have been made in recent years in the field of immunotherapy for solid tumors (1) and today there are several approved drugs available which modulate the immune response (1).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
